SCHEMBL6767433

SCHEMBL6767433

O=C(O)c1ccc(C(=O)N2Cc3ccc(C#CCc4ccccc4)cc3C2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
RARA P10276 3/20 0.37
RARB P10826 3/20 0.37
RARG P13631 3/20 0.37
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
CYP26A1 O43174 1/20 0.36
CYP3A4 P08684 1/20 0.36
CRABP2 P29373 1/20 0.36
HAO1 Q9UJM8 2/20 0.36
ALOX15 P16050 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449268 0.76 MMP13 (0.51) MMP13SLC22A8FFAR1FFAR4RARA
SCHEMBL6767426 0.74 KMT2A (0.67) MMP13SLC22A8MEN1HPGDKMT2A
SCHEMBL5697069 0.74 MMP13 (0.43) MMP13SLC22A8FFAR1FFAR4RARA
SCHEMBL5697161 0.73 MMP13 (0.43) MMP13SLC22A8FFAR1FFAR4RARA
SCHEMBL6761897 0.72 ACACB (0.44) MMP13SLC22A8HPGDHSP90AA1HSP90AB1
SCHEMBL6248628 0.72 MMP13 (0.45) MMP13SLC22A8FFAR1FFAR4RARA
SCHEMBL3241682 0.72 KMT2A (0.46) ACHEBACE1MEN1KMT2AALOX15
SCHEMBL6240857 0.71 MMP13 (0.50) MMP13SLC22A8FFAR1FFAR4MEN1
SCHEMBL6761892 0.69 GRM5 (0.47) MMP13SLC22A8MEN1HPGDKMT2A
SCHEMBL6454497 0.69 MMP13 (0.50) MMP13SLC22A8FFAR1FFAR4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US claimed
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US disclosed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis MMP13, MMP11, MMP9 MMP13 1/4885SLC22A8 404/4885FFAR1 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.